First author [Ref.] | Treatment success, n/N (%) | Adverse effects, n/N (%) |
ITT at TOCV | CE at TOCV | Hospitalisation | Patients without recurrence | Total | Patients withdrawn | Diarrhoea | All-cause mortality |
Macrolides versus quinolones | | | | | | | | |
Martinez 24 | NA | 136/151 (90) versus 133/143 (93) | 2/151 (1) versus 0/143 (0) # | NA | 16/199 (8) versus 12/190 (6) | 1/199 (0.5) versus 4/190 (2) | 10/199 (5) versus 3/190 (2) | 0/199 (0) versus 0/190 (0) |
Lode 25 | (80) versus (83) | (85) versus (86) | NA | 122/254 (48) versus 109/250 (44)¶ | 25/258 (10) versus 24/252 (10) | 12/258 (5) versus 14/252 (6) | NA | NA |
Amsden 26 | NA | 86/105 (82) versus 83/97 (86)+ | NA | NA | 21/118 (18) versus 23/117 (20) | NA | 10/118 (9) versus 5/117 (4) | NA |
Weiss 27 | NA | 80/91 (88) versus 76/87 (87) | 0/91 (0) versus 3/87 (3) | NA | NA | NA | NA | NA |
Wilson 28 | 280/358 (78) versus 279/351 (79) | 190/224 (85) versus 183/214 (86)+ | 14/224 (6) versus 5/214 (2)§ | 100/171 (58) versus 120/169 (71)ƒ | 90/358 (25) versus 66/351 (19) | 15/358 (4) versus 9/351 (3) | 25/358 (7) versus 18/351 (5) | NA |
Chodosh 29 | 268/286 (94) versus 540/569 (95) | 121/127 (95) versus 263/279 (94) | 16/312 (5) versus 21/614 (3) | NA | 103/312 (33) versus 172/614 (28) | NA | 15/312 (5) versus 33/614 (5) | 1/312 (0.3) versus 1/614 (0.2) |
DeAbate 30 | 239/261 (92) versus 228/252 (90) | 208/227 (92) versus 192/212 (91) | NA | NA | 49/284 (17) versus 61/283 (22) | 0/284 (0) versus 5/283 (2) | 19/284 (75) versus 13/283 (5) | 1/284 (0.4) versus 0/283 (0) |
Wilson 31 | 308/371 (83) versus 302/374 (81) | 289/327 (88) versus 287/322 (89) | 23/371 (6) versus 25/374 (7) | NA | 82/371 (22) versus 80/374 (21) | 14/371 (4) versus 23/374 (6) | 15/371 (4) versus 11/374 (3) | 2/371 (0.5) versus 1/374 (0.3) |
Pooled OR (95% CI) | 1.01 (0.81–1.27) | 0.94 (0.73-1.21) | 1.37 (0.75–2.50) | | 1.11 (0.94–1.32) | 0.75 (0.39–1.41) | 1.37 (0.99–1.87) | 1.96 (0.45–8.51) |
A/C versus quinolones | | | | | | | | |
Martinez 24 | NA | 103/126 (82) versus 95/120 (79) | 3/126 (2) versus 0/120 (0) | NA | 16/179 (9) versus 16/183 (9) | 1/179 (0.5) versus 5/183(3) | 5/179 (3) versus 4/183 (2) | 0/179 (0) versus 0/183 (0) |
Starakis 32 | NA | 66/74 (89) versus 70/79 (89) | 1/79 (1) versus 0/83 (0) | NA | 11/79 (14) versus 8/83 (10) | NA | 4/79 (5) versus 1/83 (1) | NA |
Schaberg 33 | 241/283 (85) versus 270/292 (93) | 230/251 (92) versus 251/261 (96) | NA | NA | 55/283 (19) versus 52/292 (18) | NA | 21/283 (7) versus 9/292 (3) | NA |
File 34 | NA | 248/266 (93) versus 247/264 (94) | NA | NA | 57/296 (19) versus 34/304 (11) | NA | 31/296 (11) versus 7/304 (2) | 0/296 (0) versus 3/304 (1) |
Pooled OR (95% CI) | NA | 0.86 (0.55-1.34) | NA | NA | 1.36 (1.01-1.85) | NA | 3.02 (1.75-5.21) | NA |
A/C versus macrolides | | | | | | | | |
Anzueto 35 | 116/143 (81) versus 117/140 (84) | 116/133 (87) versus 117/137 (85) | 3/145 (2) versus 5/142 (4) | NA | 35/145 (24) versus 28/142 (20) | 8/145 (6) versus 2/142 (1) | 18/145 (12) versus 12/142 (8) | NA |
Martinot 36 | 108/119 (90.7) versus 113/124 (91) | 96/106 (91) versus 105/113 (93) | NA | NA | 27/123 (22) versus 17/127 (13) | NA | 12/123 (10) versus 3/127 (2) | NA |
Hoepelman 37 | NA | 54/58 (89) versus 59/62 (95) | NA | NA | NA | NA | NA | NA |
Van Royen 38 | NA | 148/149 (99) versus 153/162 (94) | NA | NA | NA | NA | NA | NA |
Biebuyck 39 | 33/44 (75) versus 84/93 (90) | NA | NA | NA | NA | NA | NA | NA |
Gris 40 | NA | 24/26 (92) versus 24/28 (86) | NA | NA | NA | NA | NA | NA |
Beghi 41 | 71/73 (97) versus 46/68 (68) | 71/73 (97) versus 46/68 (68) | NA | NA | NA | NA | NA | NA |
Dautzenberg 42 | 28/33 (85) versus 29/32 (91) | 28/33 (85) versus 29/32 (91) | NA | NA | NA | NA | NA | NA |
Pooled OR (95% CI) | 1.09 (0.41–2.95) | 1.70 (0.72-4.03) | NA | NA | NA | NA | NA | NA |